AR003175A1 - A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD - Google Patents
A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOODInfo
- Publication number
- AR003175A1 AR003175A1 ARP960103860A AR10386096A AR003175A1 AR 003175 A1 AR003175 A1 AR 003175A1 AR P960103860 A ARP960103860 A AR P960103860A AR 10386096 A AR10386096 A AR 10386096A AR 003175 A1 AR003175 A1 AR 003175A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- potential
- triazol
- tumors
- mammals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se presenta una composición farmacéutica para el tratamiento de cánceres y tumores en mamíferos, que comprende 2-(2,4-difluorofenil)-1,3-bis(1H-1,2,4-triazol-1-il)propan-2-ol y sus derivados. Junto con el 2-(2,4-difluorofenil)-1,3-bis)1H-1,2,4- triazol-1-il)propan-2-ol y sus derivados puede utilizarse unagente quimioterapeútico, como así también potenciadores. El 2-(2,4- difluorofenil)-1,3-bis(1H-1,2,4-triazol-1-il)propan-2-ol y sus derivados puedenserutilizados también para el tratamiento de infecciones virósicas, ya sea solos o en combinación con otros agentes antivirósicos o con un potenciador.A pharmaceutical composition for the treatment of cancers and tumors in mammals is presented, comprising 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2 -ol and its derivatives. Together with 2- (2,4-difluorophenyl) -1,3-bis) 1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives, a chemotherapeutic agent can be used, as well as potentiators. . 2- (2,4-Difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives can also be used for the treatment of viral infections, either alone or in combination with other antiviral agents or with a booster.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US188995P | 1995-08-04 | 1995-08-04 | |
US08/674,180 US5908855A (en) | 1996-07-16 | 1996-07-16 | Compositions for treating viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AR003175A1 true AR003175A1 (en) | 1998-07-08 |
Family
ID=26669622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960103860A AR003175A1 (en) | 1995-08-04 | 1996-08-02 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0841921A2 (en) |
JP (1) | JPH11510187A (en) |
KR (1) | KR19990036138A (en) |
CN (1) | CN1195288A (en) |
AR (1) | AR003175A1 (en) |
AU (1) | AU711966B2 (en) |
BR (1) | BR9609966A (en) |
CA (1) | CA2229024A1 (en) |
CZ (1) | CZ33798A3 (en) |
HU (1) | HUP9903420A3 (en) |
IL (1) | IL123095A0 (en) |
MX (1) | MX9800998A (en) |
NO (1) | NO980473L (en) |
NZ (2) | NZ315184A (en) |
PL (1) | PL324904A1 (en) |
SK (1) | SK14198A3 (en) |
TR (2) | TR199801739T2 (en) |
WO (1) | WO1997005873A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
FR2742405B1 (en) * | 1995-12-13 | 1998-02-27 | Cgea Comp Gen Entre Auto | DRIVE UNIT COULD BE COUPLED TO A ROLLING SPEAKER AND RESULTING VEHICLE |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
PE11499A1 (en) * | 1997-05-16 | 1999-03-01 | Procter & Gamble | TREATMENT OF HIV AND CANCER |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
PT1616572E (en) * | 1998-11-09 | 2010-11-11 | Biogen Idec Inc | Chimeric anti-cd20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia |
US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6462062B1 (en) | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407105B1 (en) | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US7004915B2 (en) * | 2001-08-24 | 2006-02-28 | Kci Licensing, Inc. | Negative pressure assisted tissue treatment system |
EP1895012A1 (en) | 2006-08-30 | 2008-03-05 | Universitätsklinikum Freiburg | Method for inducing tumor apoptosis by increasing nitric oxide levels |
US20120071539A1 (en) * | 2006-12-12 | 2012-03-22 | Emory University | Compounds and methods for modulating the silencing of a polynucleotide of interest |
WO2019185521A1 (en) * | 2018-03-26 | 2019-10-03 | Westfälische Wilhelms-Universität Münster | Ergosterol-biosynthesis inhibitor and influenza virus infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0196855A3 (en) * | 1985-03-29 | 1989-04-12 | Pfizer Inc. | Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections |
BE1004029A6 (en) * | 1990-11-22 | 1992-09-08 | Mol Omer De | Pharmaceutical compound and pharmaceutical set for the treatment of cancer |
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
US5665751A (en) * | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
-
1996
- 1996-07-30 WO PCT/US1996/012474 patent/WO1997005873A2/en not_active Application Discontinuation
- 1996-07-30 AU AU66833/96A patent/AU711966B2/en not_active Ceased
- 1996-07-30 HU HU9903420A patent/HUP9903420A3/en unknown
- 1996-07-30 MX MX9800998A patent/MX9800998A/en not_active Application Discontinuation
- 1996-07-30 CZ CZ98337A patent/CZ33798A3/en unknown
- 1996-07-30 TR TR1998/01739T patent/TR199801739T2/en unknown
- 1996-07-30 CA CA002229024A patent/CA2229024A1/en not_active Abandoned
- 1996-07-30 EP EP96926806A patent/EP0841921A2/en not_active Withdrawn
- 1996-07-30 KR KR1019980700806A patent/KR19990036138A/en not_active IP Right Cessation
- 1996-07-30 TR TR1998/00270T patent/TR199800270T1/en unknown
- 1996-07-30 BR BR9609966A patent/BR9609966A/en not_active Application Discontinuation
- 1996-07-30 JP JP9508494A patent/JPH11510187A/en active Pending
- 1996-07-30 NZ NZ315184A patent/NZ315184A/en unknown
- 1996-07-30 IL IL12309596A patent/IL123095A0/en unknown
- 1996-07-30 CN CN96196682A patent/CN1195288A/en active Pending
- 1996-07-30 NZ NZ503921A patent/NZ503921A/en unknown
- 1996-07-30 PL PL96324904A patent/PL324904A1/en unknown
- 1996-07-30 SK SK141-98A patent/SK14198A3/en unknown
- 1996-08-02 AR ARP960103860A patent/AR003175A1/en not_active Application Discontinuation
-
1998
- 1998-02-03 NO NO980473A patent/NO980473L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL324904A1 (en) | 1998-06-22 |
NZ503921A (en) | 2002-03-01 |
WO1997005873A3 (en) | 1997-03-27 |
NO980473L (en) | 1998-04-03 |
MX9800998A (en) | 1998-04-30 |
TR199800270T1 (en) | 1998-05-21 |
KR19990036138A (en) | 1999-05-25 |
JPH11510187A (en) | 1999-09-07 |
EP0841921A2 (en) | 1998-05-20 |
AU6683396A (en) | 1997-03-05 |
IL123095A0 (en) | 1998-09-24 |
CZ33798A3 (en) | 1998-06-17 |
TR199801739T2 (en) | 1998-12-21 |
NZ315184A (en) | 2000-05-26 |
CN1195288A (en) | 1998-10-07 |
WO1997005873A2 (en) | 1997-02-20 |
HUP9903420A3 (en) | 2001-12-28 |
SK14198A3 (en) | 1999-03-12 |
BR9609966A (en) | 1999-02-02 |
HUP9903420A2 (en) | 2000-03-28 |
AU711966B2 (en) | 1999-10-28 |
CA2229024A1 (en) | 1997-02-20 |
NO980473D0 (en) | 1998-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003175A1 (en) | A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD | |
FR15C0057I1 (en) | ||
AR003174A1 (en) | A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION COMPRISING A POTENTIATOR, USE OF A CHEMOTHERAPEUTICAL AGENT AND A 1H-1,2-TRYZYL TREAT CANCER, TUMOR, OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD | |
BR0007500A (en) | Triazole compound, drug, and, use of the compound | |
MY116478A (en) | Tri-substituted imidazoles having multiple therapeutic properties | |
IE821285L (en) | Triazole antifungal agents | |
KR910021398A (en) | Triazole Antifungal Agents | |
TR199801323T2 (en) | Use of 1,2,4-triazole derivatives in the manufacture of a drug for the treatment of viral infections. | |
MX9605023A (en) | Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances. | |
HUP9802629A3 (en) | Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers | |
MX9800945A (en) | Use of griseofulvin for inhibiting the growth of cancers. | |
PT76846B (en) | Process for preparing triazole antifugal agents | |
KR920012049A (en) | Fluorine compounds | |
ES8406191A1 (en) | Triazole derivative as an antiviral agent | |
TR200401775T4 (en) | Branched modified novel amino derivatives of 3-Amino-1-Phenyl-1H [1,2,4] triazole, method for their manufacture and pharmaceutical compositions containing them | |
BR0017046A (en) | Use of azoles to prevent skin cancer | |
EP0367069A3 (en) | Substituted bisazoles, process for their preparation and their use as therapeutic agents | |
ES8704464A1 (en) | 4(5)-substituted imidazoles. | |
IE832183L (en) | Fungicidal agents containing triazole derivatives | |
AR015976A1 (en) | COMPOSITIONS CONTAINING HISTAMINE H2 AGONISTS FOR THE DRY EYE TREATMENT AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
HUP9801596A3 (en) | Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them | |
MX9709187A (en) | Agents for use against parasitic protozoa. | |
Greenbaum et al. | Kinin metabolism by normal and malignant leucocytes | |
RU95118900A (en) | Antitumor agent | |
AR015722A1 (en) | COMPOSITIONS FOR HAIR AND SHAMPOO CARE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |